WEBINAR | Examining synergies between regulators and ethics committees during public health emergencies

Agenda
Introduction to the Webinar
Professor Barbara Bierer, Professor of Medicine, Faculty Director, Multi-Regional Clinical Trials Center, Brigham and Women’s Hospital & Harvard, Coordinator: AVAREF & MRCT Center Ethics Training Course for AVAREF country-members’ NECs/IRBs & US Single IRB Review Project, Cambridge, MA, USA
The Expectations of Regulators for Ethics Committees During a Public Health Emergency
Dr Samvel Azatyan, Group Lead, Regulatory Convergence and Networks, World Health Organization WHO
Efficient and Quality Decision Making for Starting Clinical Trials During a Public Health Emergency
Dr Nathalie Strub-Wourgaft, Director, Neglected Tropical Diseases, Drugs for Neglected Diseases Initiative (DNDi), & Coordinator, The ANTICOV Clinical Trial (Africa), Geneva, Switzerland & Steering Committee member of the COVID-19 Clinical Research Coalition
What Are the Hurdles to Cooperation between Ethics Committees and Regulators During a Public Health Emergency?
Dr Aamir Jafarey, Professor, Centre of Biomedical Ethics and Culture, Sindh Institute of Urology and Transplantation, Pakistan; Member, National Bioethics Committee; Member, Clinical Studies Committee, Drug Regulatory Authority of Pakistan (DRAP)
Pathways to Cooperation between Ethics Committees and Regulators During Public Health Emergencies: Present Realities and Future Possibilities
Dr Fergus Sweeney, Head, Vaccines Strategy Group & Head, Inspections and Human Medicines Pharmacovigilance Division, European Medicines Agency & Co-Chair, ICH E6(R3) GCP Expert Working Group
During Public Health Emergencies
Dr Mimi Darko, CEO, Ghana Food and Drugs Authority; Chair, AVEREF Steering Committee
How to join the meeting
No registration required.
- Event link (Passcode: 123)
Organizers
Good Clinical Practice Alliance (GCPA) & the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard